Taken together, our data indicate that recombinant PTD-RBD-VIF interacts with mutant KRAS and induces its ubiquitination and degradation, thereby inhibiting the growth of pancreatic cancer cells in vitro and in vivo. This evidence concerns the gene KRAS and pancreatic neoplasm.